Marshall Wace
AYLA

Marshall Wace’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Marshall Wace’s Portfolio AYLA Stock Details AYLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23,872
Closed -$95K – 4026
2022
Q1 		$95K Sell
23,872
-25,394
-52% -$132K ﹤0.01% 3202
2021
Q4 		$420K Buy
+49,266
New +$489K ﹤0.01% 2889

Other funds holding AYLA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace's AYLA Position: Q2 2022 in Review

Marshall Wace sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q2 2022, closing a stake of 23,872 shares — an estimated $95K sold.

Marshall Wace first reported a position in AYLA in Q4 2021 and held it in 2 quarters. The position peaked at $420K in Q4 2021. 15 funds tracked by Wall St. Rank hold AYLA as of Q2 2022.

  • Marshall Wace reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Marshall Wace sold 23,872 Ayala Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $95K.
  • Marshall Wace first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Marshall Wace's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $420K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.